Prof. Ipsita Roy
University of Westminster, United Kingdom
Professor Ipsita Roy is an expert in microbial biotechnology, natural biomaterials and their biomedical applications. She is currently a Professor at the Faculty of Science and Technology, University of Westminster, London. Ipsita was awarded the prestigious Inlaks Scholarship and the Overseas Research Students Award to study for her Ph.D. at the University of Cambridge. During her time at Cambridge she was awarded the Churchill College Scholarship, the Lundgren Scholarship, Leche Trust Scholarship and the Cambridge University Philosophical Society Fellowship Award. Her PhD at the Department of Biochemistry was on a B12-dependent enzyme, methylmalonyl-CoA mutase. Her postdoctoral work was at the University of Minnesota, USA, at the Bioprocess Technology Institute, where she worked on fatty acid biosynthesis.
Subsequently, Professor Roy taught at the Indian Institute of Technology, India, for four years as an Assistant Professor. During this time she worked actively on the production of biodegradable polymers from Streptomyces. Ipsita has been at the University of Westminster since 2000 and leadsthe Applied Biotechnology Research Group. She has published over 100 papers in high ‘Impact Factor’ journals such as Biomaterials, Biomacromolecules, Journal of Royal Society Interface. She haspresented her work at numerous international conferences. Her group is currently focussed on the production of novel polyhydroxyalkanoates (PHAs), a group of FDA-approved natural polymers and their characterisation. She has pioneered the production of PHAs from Gram positive bacteria which lack immunogenic properties and hence are excellent materials for medical applications. Her group is involved in the application of PHAs in the area of hard tissue engineering, soft tissue engineering, wound healing and drug delivery. She is an editor of the Journal of Chemical Technology and Biotechnology (JCTB) and was the special editor of an In Focus Issue of JCTB on Biodegradable polymers and Controlled Drug Delivery. She is on the BBSRC, EPSRC, NSERC, Canada, FWF, Austria and NSFC, China, ESF, MUIR grant-reviewing panels. Her work has been funded by the EPSRC, EU, DuPont and WESTFOCUS, London. Ipsita is currently the scientific coordinator of two large EU projects REBIOSTENT, worth 4.9 million Euros with 14 consortium members and HYMEDPOLY, worth 3.5 million Euros with 12 consortium members, She was also the work package leader of another large EU FP7 project, NEURIMP, worth 4.4 million Euros with 8 consortium members. Recently she has initiated working on another H2020 project POLBIOSKIN worth 3 million Euros with 12 consortium members. All four projects involve the use of PHAs for medical applications, drug eluting biodegradable stents, nerve guidance conduits, antibacterial polymers and wound healing.